Wedbush Reiterates Outperform Rating for AnaptysBio (NASDAQ:ANAB)
AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Wedbush in a report issued on Wednesday,RTT News reports. They presently have a ...
Vanda Pharmaceuticals targets total annual revenue in excess of $1B in 2030
For the psychiatry portfolio alone, Vanda is targeting annual revenue in excess of $750M in 2030, assuming the potential approval of Bysanti ...
Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year?
Here is how AnaptysBio, Inc. (ANAB) and AtriCure (ATRC) have performed compared to their sector so far this year.
H.C. Wainwright lifts AnaptysBio stock target to $22, keeps Neutral
H.C. Wainwright analyst Emily Bodnar increased the price target on AnaptysBio (NASDAQ:ANAB) shares to $22.00, up from the previous $19.00, while maintaining a Neutral rating on the stock. According to ...
AnaptysBio price target raised to $51 from $40 at Wells Fargo
Wells Fargo raised the firm’s price target on AnaptysBio (ANAB) to $51 from $40 and keeps an Overweight rating on the shares. The firm believes ...
AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains?
AnaptysBio (ANAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...